## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 2.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (48% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Pacer Advisors Inc. Has $5.24 Million Stake in GE HealthCare Technologies Inc. $GEHC**
- Source: MarketBeat | 20251230T111205 | Somewhat-Bullish | Relevance: 100%
- Pacer Advisors Inc. reduced its stake in GE HealthCare Technologies by 16.8% to 69,744 shares, now valued at approximately $5.24 million, although institutional investors overall own 82.06% of the stock. Despite a split among analysts, the consensus is a "Moderate Buy" with an average price target of $87.09, reflecting recent target increases by several firms. GE HealthCare exceeded Q3 earnings estimates with EPS of $1.07 and revenue of $5.14 billion, and has provided FY25 guidance of $4.51–$4.63 EPS.

**2. GE HealthCare Technologies Inc. $GEHC Shares Acquired by Valicenti Advisory Services Inc.**
- Source: MarketBeat | 20251228T115724 | Bullish | Relevance: 100%
- Valicenti Advisory Services Inc. increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 22.6% in the third quarter, now holding 68,107 shares valued at $5.12 million. Other institutional investors like Dodge & Cox, Norges Bank, and Holocene Advisors LP have also made significant moves in GEHC shares, with 82.06% of the stock owned by institutional investors. Despite a "Moderate Buy" consensus rating and an average price target of $87.09 from Wall Street analysts, the company's financial performance shows a market cap of $38.1 billion and recent positive quarterly earnings results.

**3. GE HealthCare CEO Peter Arduini is forging a new chapter while drawing on Jack Welch’s legacy**
- Source: Fortune | 20251228T110202 | Bullish | Relevance: 91%
- GE HealthCare CEO Peter Arduini discusses leading the company post-spin-off from General Electric, drawing on GE's legacy and Jack Welch's leadership principles while adapting to modern medical technology and digital health landscapes. He highlights the company's significant increase in R&D investment and focus on lean principles, innovation, and global market strategies, particularly in China. Arduini emphasizes authenticity, communication, and empowering employees to live the company's values in his leadership approach.

**4. Japan's Telemedicine and AI-Driven Healthcare Adoption Propel Growth in the Digital Health Market | Top Companies - Koninklijke Philips N.V., Medtronic plc, GE HealthCare, Siemens Healthineers, Teladoc Health**
- Source: openPR.com | 20251230T090934 | Somewhat-Bullish | Relevance: 87%
- The digital health market is projected to grow at a CAGR of 20.6% during 2025-2033, reaching US$ 1,907.21 billion by 2033, driven by rapid adoption of telemedicine, wearable devices, mobile health applications, and AI-driven solutions. Japan, in particular, is witnessing significant advancements with AI-powered platforms, mobile health apps, telemedicine collaborations, and insurance reimbursements for digital therapeutics. The Asia Pacific region leads the market with a 45% share due to increasing adoption and government initiatives.

**5. The Future of Bone Sonometer Market 2032 Industry Forecast**
- Source: openPR.com | 20251229T072740 | Bullish | Relevance: 83%
- The Bone Sonometer Market is projected to grow from USD 1,336.8 Mn in 2025 to USD 1,996.8 Mn by 2032, exhibiting a CAGR of 5.9%. This growth is driven by rising industry demand, expanding applications, and technological advancements, according to a report by Coherent Market Insights. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscape, with a detailed regional assessment to inform strategic business decisions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.50 elevated, pricing in significant growth expectations. Forward P/E 16.9x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.0B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.50 |
| Forward P/E | 16.9 |
| Current P/E | 18.3 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -0.2% (minimal 5-day change). Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). RSI neutral at 57. Volume at 48% of 20MA suggests lack of conviction. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.20% (CS: 41) | Neutral |
| RSI_14 | 57.0 | Neutral |
| MACD Histogram | -0.32 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.33
- **Stop Loss:** $80.05 (3.9% risk)
- **Target:** $86.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 402
- **Position Value:** $33,498.66
- **Portfolio %:** 33.50%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*